세계의 황반변성 치료제 시장 규모 조사 : 유형별, 단계별, 치료 유형별, 판매 채널별, 지역별 전망(2022-2032년)

Global macular degeneration treatment market is valued at approximately USD 10.65 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.80% over the forecast period 2024-2032. Macular degeneration treatment primarily focuses on slowing the disease's progression and improving vision quality. For dry macular degeneration, treatments include nutritional supplements like vitamins C and E, lutein, and zinc. For wet macular degeneration, anti-VEGF injections, such as ranibizumab and aflibercept, are commonly used to reduce abnormal blood vessel growth and leakage. Photodynamic therapy and laser surgery are other options for specific cases. Lifestyle changes, including a healthy diet, regular exercise, and quitting smoking, also play a crucial role in managing the condition and maintaining overall eye health.

The burgeoning aging population worldwide is a key catalyst propelling the growth of the Global Macular Degeneration Treatment Market. As individuals age, the prevalence of macular degeneration, a degenerative eye condition, increases significantly. This demographic shift creates a substantial market demand for innovative and effective treatment solutions, driving investment and research in the field. The rising incidence of age-related macular degeneration (AMD) fuels the demand for therapeutic interventions, such as pharmaceuticals and advanced medical technologies, to address the specific needs of the aging demographic. Additionally, the increasing awareness and proactive healthcare approaches among the elderly contribute to the market expansion.

The Global Macular Degeneration Treatment Market is significantly propelled by the increasing awareness and proactive screening programs. Heightened public consciousness about the risks and symptoms of macular degeneration has led to a rise in early diagnosis, creating a surge in demand for effective treatment options. As individuals become more informed about the importance of regular eye check-ups, they are increasingly likely to seek medical attention for early detection of macular degeneration, fostering a robust market ecosystem. Government initiatives and private sector organizations are actively contributing to the expansion of screening programs, amplifying the market reach. Also, government initiatives and funding support substantially influence the growth trajectory of the Global Macular Degeneration Treatment Market. Governments worldwide are recognizing the escalating impact of macular degeneration on public health, prompting them to implement strategic measures that drive advancements in treatment solutions. Financial support from governmental bodies bolsters research and development efforts, fostering innovation in pharmaceuticals and medical technologies specifically tailored for macular degeneration. Government initiatives often include funding programs, grants, and collaborative partnerships with the private sector to accelerate the development of effective treatments.

The key regions considered for the Global Macular Degeneration Treatment market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is poised to be a key driver in the growth of the Global Macular Degeneration Treatment Market. The region exhibits a robust healthcare infrastructure, coupled with a high prevalence of age-related macular degeneration (AMD) within its aging population. The significant healthcare expenditures and advanced medical research capabilities in North America create an environment conducive to the development and adoption of cutting-edge macular degeneration treatments. The region's proactive regulatory framework and well-established reimbursement mechanisms facilitate the swift approval and accessibility of innovative therapies.

Major market players included in this report are:

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc.

The detailed segments and sub-segment of the market are explained below:

By Type:

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

By Stage of Disease:

• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

By Treatment Type:

• Drug
• Devices
• Surgery

By Sales Channel:

• Ambulatory Surgical Centers
• Hospitals
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Macular Degeneration Treatment Market Executive Summary

• 1.1. Global Macular Degeneration Treatment Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Stage of Disease
  • 1.3.3. By Treatment Type
  • 1.3.4. By Sales Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Macular Degeneration Treatment Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Macular Degeneration Treatment Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Aging Population Demographics
  • 3.1.2. Growing Awareness and Screening Programs
  • 3.1.3. Government Initiatives and Funding Support
• 3.2. Market Challenges
  • 3.2.1. Limited Awareness in Underserved Regions
  • 3.2.2. Complexity in Supply Chain
• 3.3. Market Opportunities
  • 3.3.1. Personalized Medicine Advancements
  • 3.3.2. Development of Novel Therapies

Chapter 4. Global Macular Degeneration Treatment Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Macular Degeneration Treatment Market Size & Forecasts by Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Macular Degeneration Treatment Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Dry Age-related Macular Degeneration
  • 5.2.2. Wet Age-related Macular Degeneration

Chapter 6. Global Macular Degeneration Treatment Market Size & Forecasts by Stage of Disease 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Macular Degeneration Treatment Market: Stage of Disease Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Early-stage AMD
  • 6.2.2. Intermediate AMD
  • 6.2.3. Late-stage AMD

Chapter 7. Global Macular Degeneration Treatment Market Size & Forecasts by Treatment Type 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Macular Degeneration Treatment Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Drug
  • 7.2.2. Devices
  • 7.2.3. Surgery

Chapter 8. Global Macular Degeneration Treatment Market Size & Forecasts by Sales Channel 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Macular Degeneration Treatment Market: Sales Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Ambulatory Surgical Centers
  • 8.2.2. Hospitals
  • 8.2.3. Others

Chapter 9. Global Macular Degeneration Treatment Market Size & Forecasts by Region 2022-2032

• 9.1. North America Macular Degeneration Treatment Market
  • 9.1.1. U.S. Macular Degeneration Treatment Market
    • 9.1.1.1. Type breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Stage of Disease breakdown size & forecasts, 2022-2032
    • 9.1.1.3. Treatment Type breakdown size & forecasts, 2022-2032
    • 9.1.1.4. Sales Channel breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Macular Degeneration Treatment Market
• 9.2. Europe Macular Degeneration Treatment Market
  • 9.2.1. UK Macular Degeneration Treatment Market
  • 9.2.2. Germany Macular Degeneration Treatment Market
  • 9.2.3. France Macular Degeneration Treatment Market
  • 9.2.4. Spain Macular Degeneration Treatment Market
  • 9.2.5. Italy Macular Degeneration Treatment Market
  • 9.2.6. Rest of Europe Macular Degeneration Treatment Market
• 9.3. Asia-Pacific Macular Degeneration Treatment Market
  • 9.3.1. China Macular Degeneration Treatment Market
  • 9.3.2. India Macular Degeneration Treatment Market
  • 9.3.3. Japan Macular Degeneration Treatment Market
  • 9.3.4. Australia Macular Degeneration Treatment Market
  • 9.3.5. South Korea Macular Degeneration Treatment Market
  • 9.3.6. Rest of Asia Pacific Macular Degeneration Treatment Market
• 9.4. Latin America Macular Degeneration Treatment Market
  • 9.4.1. Brazil Macular Degeneration Treatment Market
  • 9.4.2. Mexico Macular Degeneration Treatment Market
  • 9.4.3. Rest of Latin America Macular Degeneration Treatment Market
• 9.5. Middle East & Africa Macular Degeneration Treatment Market
  • 9.5.1. Saudi Arabia Macular Degeneration Treatment Market
  • 9.5.2. South Africa Macular Degeneration Treatment Market
  • 9.5.3. Rest of Middle East & Africa Macular Degeneration Treatment Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. F. Hoffmann-La Roche Ltd
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. Novartis AG
  • 10.3.3. Pfizer Inc.
  • 10.3.4. PanOptica Inc.
  • 10.3.5. Bausch Health Companies Inc.
  • 10.3.6. Regeneron Pharmaceuticals Inc.
  • 10.3.7. Aerie Pharmaceutical Inc.
  • 10.3.8. REGENXBIO Inc.
  • 10.3.9. Bayer AG
  • 10.3.10. Lineage Cell Therapeutics Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes